PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Cortes, J. [1 ]
O'Connell, A. [2 ]
Shaik, M. N. [3 ]
Cesari, R. [4 ]
Abbattista, A. [4 ]
Woolfson, A. [5 ]
Pollyea, D. [6 ]
Savona, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Pfizer Oncol, Collegeville, PA USA
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Milan, Italy
[5] Pfizer Oncol, New York, NY USA
[6] Univ Colorado, Ctr Canc, Aurora, CO USA
[7] Tennessee Oncol, Nashville, TN USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P179
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [21] Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS)
    Macdonald, D. A.
    Assouline, S. E.
    Brandwein, J.
    Kamel-Reid, S.
    Eisenhauer, E. A.
    Couban, S.
    Foo, A.
    Leber, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline
    Fukushima, Toshihiro
    Kawabata, Hiroshi
    Sawaki, Toshioki
    Satoh, Tomomi
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Sakai, Tomoyuki
    Miki, Miyuki
    Fujita, Yoshimasa
    Tanaka, Masao
    Kawanami, Takafumi
    Masaki, Yasufumi
    Okazaki, Toshiro
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2012, 32 (04) : 1347 - 1353
  • [23] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Daver, Naval Guastad
    Kantarjian, Hagop M.
    Pierce, Sherry
    Brandt, Mark
    Dinardo, Courtney Denton
    Pemmaraju, Naveen
    Vaughan, Kenneth
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan M.
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Phase I evaluation of tipifarnib in combination with low dose Ara-C (LDAC) in high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): final results
    Feldman, E. J.
    Douer, D.
    Walsh, W.
    Moyo, V. M.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Farnesyl transferase inhibitor (tipifarnib, zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-c) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Verstovsek, S
    Estrov, Z
    Giles, F
    Ravandi, F
    Wright, J
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 784A - 784A
  • [26] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study
    Halpern, Anna B.
    Estey, Elihu H.
    Othus, Megan
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Chen, Tara L.
    Becker, Pamela S.
    Scott, Bart L.
    Hendrie, Paul C.
    Ostronoff, Fabiana
    Ranker, Elizabeth M.
    Shadman, Mazyar
    Stirewalt, Derek L.
    Walter, Roland B.
    BLOOD, 2014, 124 (21)
  • [27] A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Saygin, Caner
    Larkin, Karilyn
    Blachly, James S.
    Orwick, Shelley
    Ngankeu, Apollinaire
    Gregory, Charles T.
    Phelps, Mitch A.
    Mani, Shylaja
    Walker, Alison
    Garzon, Ramiro
    Vasu, Sumithira
    Walsh, Katherine J.
    Bhatnagar, Bhavana
    Klisovic, Rebecca B.
    Grever, Michael R.
    Marcucci, Guido
    Byrd, John C.
    Blum, William
    Mims, Alice S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1457 - 1465
  • [28] Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
    Amador-Medina, Lauro Fabian
    Crespo-Solis, Erick
    Turrubiates-Herna, Francisco Javier
    Santibanez-Bedolla, Karla Edith
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S322 - S331
  • [29] Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)
    Kyo, Taiichi
    Yoshida, Noriaki
    Kyo, Kouhei
    Okatani, Takeshi
    Itagaki, Mitsuhiro
    Yuasa, Hiromi
    Iwato, Koji
    Asaoku, Hideki
    Katayama, Yuuta
    BLOOD, 2010, 116 (21) : 1209 - 1210
  • [30] Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results
    Loges, Sonja
    Heuser, Michael
    Chromik, Jolanta
    Sutamtewagul, Grerk
    Kapp-Schwoerer, Silke
    Crugnola, Monica
    Di Renzo, Nicola
    Lemoli, Roberto Massimo
    Mattei, Daniele Giovanni
    Ben Batalla, Isabel
    Waizenegger, Jonas
    Janning, Melanie
    Rieckmann, Lisa-Marie
    Imbusch, Charles
    Beumer, Niklas
    Micklam, David
    Gorcea-Carson, Claudia
    Oliva, Cristina
    Fiedler, Walter
    Alvarado-Valero, Yesid
    McCracken, Nigel
    Gjertsen, Bjorn T.
    BLOOD, 2023, 142
12345